TRV GP’s Carisma Therapeutics CARM Stock Holding History

TRV GP’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-204,580	Closed	-$18.9M	–	1
2021 Q2	$18.9M	Hold	204,580	–	–	100%	1
2021 Q1	$10.6M	Sell	204,580 -37,500	-15%	-$1.77M	100%	1
2020 Q4	$6.54M	Hold	242,080	–	–	100%	1
2020 Q3	$6.78M	Hold	242,080	–	–	100%	1
2020 Q2	$3.49M	Hold	242,080	–	–	7.64%	2
2020 Q1	$2.72M	Hold	242,080	–	–	5.33%	2
2019 Q4	$5.04M	Hold	242,080	–	–	3.4%	2
2019 Q3	$5.67M	Hold	242,080	–	–	8.89%	3
2019 Q2	$7.26M	Hold	242,080	–	–	8.22%	3
2019 Q1	$4.99M	Hold	242,080	–	–	4.94%	3
2018 Q4	$6.88M	Hold	242,080	–	–	6.86%	3
2018 Q3	$10.4M	Hold	242,080	–	–	8.66%	3
2018 Q2	$9.44M	Hold	242,080	–	–	5.95%	3
2018 Q1	$5.08M	Hold	242,080	–	–	3.6%	4
2017 Q4	$3.92M	Buy	+242,080	New	+$4.5M	1.77%	4

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

TRV GP's CARM Position: Q3 2021 in Review

TRV GP sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 204,580 shares — an estimated $18.9M sold.

TRV GP first reported a position in CARM in Q4 2017 and held it in 15 quarters. The position peaked at $18.9M in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

TRV GP reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
TRV GP sold 204,580 Carisma Therapeutics shares in Q3 2021, an estimated $18.9M.
TRV GP first reported a position in Carisma Therapeutics in Q4 2017 and held it in 15 quarters.
TRV GP's Carisma Therapeutics position peaked at $18.9M in Q2 2021.
103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on TRV GP's 13F filing for Q3 2021.